

# The Evolving Universe of GLP-1 Medicines

## Key Takeaways

- ▶ GLP-1RA offer hope for the future treatment of metabolic diseases
- ▶ New treatments add GIP, glucagon, amylin, or PYY to the GLP-1
- ▶ Many new dual, triple, or even quadruple agonists may come to market
- ▶ These may offer tailored approaches to not just weight loss, but for metabolic CV, liver, or kidney disease
- ▶ Administration options may also evolve – perhaps moving to monthly injections; there are also attempts at gene editing and cell-based therapies
- ▶ Possible new indications include osteoarthritis, sleep apnea, Parkinson's, Alzheimer's, etc.

CV, cardiovascular; GIP, glucose-dependent insulintropic polypeptide; GLP-1RA, glucagon-like peptide-1 receptor agonist; PYY, peptide YY

**Source:** Drucker DJ. Interview: The Evolving Universe of GLP-1 Medicines. [The Best of Obesity Week. November, 2024.](#)